Dr. Reddy's Has All Guns Blazing On Biosimilars; Plans To Go After Top 10
This article was originally published in The Pink Sheet Daily
Executive Summary
The Indian company has captured over half of the rituximab segment in the local market, earning close to $6 million in just over a year's time after launch of Rituxan generic Reditux.
You may also be interested in...
Partnering Better Than Solo Play For Biosimilars, Says Dr. Reddy's CEO; Limited Growth In Generics Will Lead To Moves For Innovative Drugs
MUMBAI - With six biosimilar compounds in the works and two launched in the Indian market, India's second largest generic drug maker - Dr. Reddy's Labs - is negotiating with several multinational companies to broaden its presence in Western markets
Dr. Reddy’s Labs Vice Chairman G. V. Prasad On Challenges And Opportunities In The Global Generic Drugs Industry: An Interview With PharmAsia News
In the ever-evolving pharmaceutical world, where Big Pharma is increasingly seeing common goals in aligning with generic drug companies, GlaxoSmithKline and Dr. Reddy's Labs recently entered into a strategic alliance to reach out to untapped emerging markets for generic drugs. While it is apparent that large pharmaceutical companies see emerging markets as their next big bet, how are generic drug makers responding? To find out, PharmAsia News India bureau caught up with G.V. Prasad, vice chairman of Dr. Reddy's Labs, who shaped the future for his company, from generic drugs to researching new compounds.
GSK In Pact With India’s Dr Reddy’s; Digs Deeper Into Emerging Generic Drugs Market
MUMBAI - Expanding its reach further into emerging markets for generic drugs, GlaxoSmithKline said it has reached an agreement with Dr. Reddy's Labs to develop and market select products across an extensive number of countries, except India